Headline: Illumina (ILMN) Beats Q4 Earnings, Exceeds Analysts' Estimates - 02/09/2026

[Para 1: The Lead] Illumina (NASDAQ:ILMN) exceeded market expectations in Q4, reporting revenues of $1.08 billion, up 1.8% year-over-year, and adjusted earnings of $1.25 per share, surpassing analysts' guidance. The company's strong performance is set to influence the life sciences tools & services sector. [Para 2-3: Supporting details & Context] Analysts are forecasting a 1.8% year-over-year revenue growth to $1.12 billion and an earnings per share of $1.25 for the current quarter. Illumina has consistently beaten Wall Street's revenue estimates, exceeding them by an average of 0.8% over the past two years. Comparatively, peers like Thermo Fisher (TMO) and Revvity (RVTY) have also outperformed, with Thermo Fisher's shares down 4.8% and Revvity's down 7.1% post-earnings. Despite this, Illumina's share price has fallen 4% over the past month, trading at $135.33, with an average analyst price target of $135.94. The company's resilience and strong earnings indicate a positive outlook for investors.